NCPA issued gratitude to Sens. Cantwell and Grassley for their efforts to "pull back the curtain on PBMs and push for FTC review of anticompetitive PBM practices."
DSN's editor-in-chief Nigel Maynard takes a look at the pace of congressional legislation on issues that are important to retail pharmacies, such as PBM reform and patient access.
The organization publicly commends the administration’s efforts to standardize plan choice by requiring generic drugs be placed on generic tiers and brand-name drugs on brand-name tiers.
In its 90th year, NACDS remains focused on the ever-evolving goal of leading the future of an industry dedicated to advancing health and wellness for all Americans.
Briumvi is used to treat relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, in adults.
The law change removes the federal requirement for practitioners to have a DATA-Waiver registration to prescribe buprenorphine for the treatment of opioid use disorder.
